NEWSWIRETODAY Press Release& Newswire Distribution | HOME
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Bio-Synthesis, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bio-Synthesis Examined New Benefits and Uses of Anti-drug Antibodies - The uses and benefits of anti-drugs antibodies is examined by Bio-Synthesis, Inc
Bio-Synthesis Examined New Benefits and Uses of Anti-drug Antibodies


NewswireToday - /newswire/ - Lewisville, TX, United States, 2009/11/23 - The uses and benefits of anti-drugs antibodies is examined by Bio-Synthesis, Inc.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Pharmaceutical industries are increasingly using biological or biotechnological products for drug development. The biologics or biopharmaceuticals, as they are commonly called, are generally composed of large, complex proteins which may or may not be glycosylated and are of human, plant or animal origin. These products have the potential to induce anti-drug-antibody (ADA) or cell-mediated immune response in patients. The immune response can range from a transient appearance of antibodies without any clinical significance to severe life threatening conditions such as severe hypersensitivity-type reactions, decrease in efficacy and induction of autoimmunity, including antibodies to the endogenous form of the protein. Anti-Drug Antibody (ADA) responses can lead to allergic reactions, reduction or neutralization of drug activity and potential cross reactivity. Moreover, in preclinical studies, ADA can affect drug exposure, affecting the interpretation of the toxicity, pharmacokinetic and pharmaco-dynamic data.

Factors causing immunogenicity
The factors that cause immunogenicity of these products could be patient-related, disease-related and product-related. The patient-related factors could be: genetic factors, age of the patient, disease related factors including other treatments and exposure to similar immunogens owing to concomitant treatment, duration, route of administration and treatment modalities, and previous exposure to similar products. The patient’s underlying disease can also be responsible for inducing immunogenicity. Some patients with chronic infections may be more prone to an immune response against a therapeutic protein. Patients with autoimmune disease, with an altered immunological tolerance to self-proteins, may react differently. In some conditions such as malnutrition, advanced metastatic disease, organ failure, an immune response against a therapeutic protein might be less likely to occur due to an impaired immune system. For some products, it has been reported that the susceptibility to an antibody response can be different for different indications. Product-related factors that might influence an immune response are: the origin and nature of the active substance (structural homology, post translational modifications), modification of the native protein (e.g. pegylation), product and process related impurities such as break down products, aggregates and host cell proteins, source of the protein, manufacturing process (impurity profile, contaminants), formulation and stability characteristics (degradation products, aggregates) of the protein, its dose, dosing interval and duration of treatment.

Thus to ensure clinical safety and efficacy of the numerous biologics used in drug development, immunogenicity testing has become very vital. Food and Drug Administration (FDA) in the USA has a policy to include immunogenicity as part of the review of clinical safety assessments for biologic license applications. Similar requirements exist for other regulatory agencies such as European Medicines Agency (EMEA) in Europe. However as of now, no comprehensive guidelines exist on the approaches that are required for immunogenicity testing during product development. Similarly, there is no single source of the requirements for non-clinical or clinical studies and no specific guidance for performing or interpreting assays.

The various analytical approaches that have been used to monitor or detect the presence of antidrug antibodies in the last couple of decades are:
1) Immunological based technologies (e. g. Western blots, immunoassay);
2) Chromatographic formats (e.g. size exclusion, capillary electrophoresis);
3) Surface plasma resonance biosensors and
4) Bioassays (e. g. immortalized cell lines).

Antibodies are needed for western blot, immune precipitation, and protein purification among other methods. Manufacturing a protein made recombinant involves cumbersome steps - cloning the cDNA, expressing the protein and purifying the protein. These processes can be bypassed by outsourcing the whole process of manufacturing the peptides or the antibodies to a vendor who can synthesize the specific peptides of choice as well as manufactures antibodies.

Synthetic peptides could be used for the following purposes:
• To verify the structure of naturally occurring peptides;

• To study the relationship between structure and activity of biologically active proteins and peptides and establish their molecular mechanisms and

• To develop new peptide-based immunogens, antibodies, hormones, vaccines, etc.
Synthetic peptides may range from 2 to 120 amino acids. Small synthetic peptides (in general less than 10 amino acids in length) have the advantage of rarely inducing antibody formation and can be tailored to move across blood brain barrier. Peptides for antibody production are generally of 15 to 25 amino acids. Such peptides can be conjugated to a protein carrier such as KLH, BSA etc. which can induce antibody production and used for both in vitro and in vivo assays.

About Bio-Synthesis
Bio-Synthesis Inc, headquartered in Lewisville, Texas is a leading biomedical manufacturer of custom peptide synthesis, polyclonal antibodies, bioconjugates, DNA oligomer, HLA/DNA typing, organic synthesis and a diverse number of bimolecular products for the biomedical/life science community worldwide. Our staff of highly experienced and qualified chemists, biologists and immunologists has reliably and consistently provided products and services to large pharmaceuticals and universities across the country that meet the most demanding requirements for quality, turnaround and expert technical support.

We have capabilities to synthesize over thousands peptides simultaneously with over 22 years of experienced manufacturing. We believe our quality control and speed is unmatched in the industry. Our organic synthesis divisions have successfully completed a number of projects with various biotechnology companies.

For more information, please call 1-800-227-0627.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Bio-Synthesis, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Bio-Synthesis Examined New Benefits and Uses of Anti-drug Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
Publisher Contact: Angela Ragan - 
972-420-8505 angela_ragan[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio-Synthesis, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Bio-Synthesis, Inc. / Company Profile

Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  The Franchise Group

Visit  Mokuyobi

  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (